Recent Updates
Recently added Catalysts
MYO Positive Sentiment

Myomo Reports Second Quarter 2026 Financial and Operating Results

Wednesday, August 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Myomo, Inc. reported its financial results for Q2 2026, highlighting a revenue of $11.7 million, which surpassed expectations. The company attributes this success to an evolved go-to-market strategy aimed at enhancing its offerings for individuals with neurological disorders and upper-limb paralysis. Overall, the results indicate a positive trajectory for Myomo.

Market Sentiment Analysis

POSITIVE FACTORS

  • Revenue of $11.7 million exceeded expectations.
  • The evolution of the go-to-market approach is yielding positive results.
  • The company is focused on providing solutions for neurological disorders.

Full Press Release Details

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO)(“Myomo” or the “Company”), a wearable medical robotics platform company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and six months ended June 30, 2026. “I am pleased to report that the evolution of our go-to-market approach is driving positive results. Revenue of $11.7 million exceeded our expectations, with 53% of

Frequently Asked Questions

What were Myomo's Q2 2026 revenue figures?

Myomo reported a revenue of $11.7 million for Q2 2026.

How did Myomo's revenue compare to expectations?

The revenue exceeded expectations, indicating positive growth.

What is Myomo's focus in its market strategy?

Myomo focuses on providing solutions for neurological disorders and upper-limb paralysis.

ShareAdd on Google
Tags: MYO Viatris Investor Conferences Healthcare Myomo financial results revenue neurological disorders
Last updated: Aug 5, 2026

Biotech snapshot

Cash runway
$16M liquidity · $1M/mo burn
~18 mo
Low dilution risk